These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 33722949)

  • 1. Risk of Severe COVID-19 Infection in Patients With Inflammatory Rheumatic Diseases.
    Bachiller-Corral J; Boteanu A; Garcia-Villanueva MJ; de la Puente C; Revenga M; Diaz-Miguel MC; Rodriguez-Garcia A; Morell-Hita JL; Valero M; Larena C; Blazquez-Cañamero M; Guillen-Astete CA; Garrote S; Sobrino C; Medina-Quiñones C; Vazquez-Diaz M
    J Rheumatol; 2021 Jul; 48(7):1098-1102. PubMed ID: 33722949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
    Hasseli R; Mueller-Ladner U; Schmeiser T; Hoyer BF; Krause A; Lorenz HM; Regierer AC; Richter JG; Strangfeld A; Voll RE; Pfeil A; Schulze-Koops H; Specker C
    RMD Open; 2020 Sep; 6(2):. PubMed ID: 32878994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark.
    Cordtz R; Lindhardsen J; Soussi BG; Vela J; Uhrenholt L; Westermann R; Kristensen S; Nielsen H; Torp-Pedersen C; Dreyer L
    Rheumatology (Oxford); 2021 Oct; 60(SI):SI59-SI67. PubMed ID: 33369663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.
    Loarce-Martos J; García-Fernández A; López-Gutiérrez F; García-García V; Calvo-Sanz L; Del Bosque-Granero I; Terán-Tinedo MA; Boteanu A; Bachiller-Corral J; Vázquez-Díaz M
    Rheumatol Int; 2020 Dec; 40(12):2015-2021. PubMed ID: 32945944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Filipinos with inflammatory rheumatic diseases developing COVID-19 prior to vaccinations and new variants: a historical perspective.
    Zamora-Abrahan GT; Salido EO; Lichauco JJT; Gutierrez-Rubio AKM; Rivera-Go ICT; Cortez KJC; Suilan KEA; Villo JGB; Del Rosario AG
    Clin Rheumatol; 2023 Apr; 42(4):1171-1175. PubMed ID: 36637634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Influence of Corticosteroids, Immunosuppressants and Biologics on Patients With Inflammatory Bowel Diseases, Psoriasis and Rheumatic Diseases in the Era of COVID-19: A Review of Current Evidence.
    Zhang M; Bai X; Cao W; Ji J; Wang L; Yang Y; Yang H
    Front Immunol; 2021; 12():677957. PubMed ID: 34335579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
    Chiu YM; Chen DY
    Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
    [No Abstract]   [Full Text] [Related]  

  • 8. COVID-19 Among Patients With Inflammatory Rheumatic Diseases.
    Esatoglu SN; Tascilar K; Babaoğlu H; Bes C; Yurttas B; Akar S; Pehlivan O; Akleylek C; Tecer D; Seyahi E; Yuce-Inel T; Alpay-Kanitez N; Bodakci E; Tekgoz E; Colak S; Bolek EC; Koca SS; Kalyoncu U; Icacan OC; Ugurlu S; Oz HE; Hamuryudan V; Hatemi G;
    Front Immunol; 2021; 12():651715. PubMed ID: 33936073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients.
    Zen M; Fuzzi E; Astorri D; Saccon F; Padoan R; Ienna L; Cozzi G; Depascale R; Zanatta E; Gasparotto M; Benvenuti F; Bindoli S; Gatto M; Felicetti M; Ortolan A; Campaniello D; Larosa M; Lorenzin M; Ramonda R; Sfriso P; Schiavon F; Iaccarino L; Doria A
    J Autoimmun; 2020 Aug; 112():102502. PubMed ID: 32527675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of Covid-19 in patients with rheumatic diseases and the effects of the pandemic on rheumatology outpatient care: A single-centre experience from Turkey.
    Batıbay S; Koçak Ulucaköy R; Özdemir B; Günendi Z; Göğüş FN
    Int J Clin Pract; 2021 Sep; 75(9):e14442. PubMed ID: 34105856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of patients with COVID-19 and inflammatory rheumatic diseases receiving biological/targeted therapy.
    Pehlivan Ö; Aydin T
    Ann Saudi Med; 2022; 42(3):155-164. PubMed ID: 35658585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Risk Factors for COVID-19 Hospitalization in Patients With Anti-Rheumatic Drugs: Results From a Multicenter Nested Case Control Study.
    Opdam MAA; Benoy S; Verhoef LM; Van Bijnen S; Lamers-Karnebeek F; Traksel RAM; Vos P; den Broeder AA; Broen J
    Clin Pharmacol Ther; 2022 May; 111(5):1061-1065. PubMed ID: 35143039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sociodemographic and clinical factors associated with poor COVID-19 outcomes in patients with rheumatic diseases: data from the SAR-COVID Registry.
    Isnardi CA; Roberts K; Saurit V; Petkovic I; Báez RM; Quintana R; Tissera Y; Ornella S; D Angelo Exeni ME; Pisoni CN; Castro Coello VV; Berbotto G; Haye Salinas MJ; Velozo E; Reyes Torres ÁA; Tanten R; Zelaya MD; Gobbi C; Alonso CG; de Los Ángeles Severina M; Vivero F; Paula A; Cogo AK; Alle G; Pera M; Nieto RE; Cosatti M; Asnal C; Pereira D; Albiero JA; Savio VG; Maldonado FN; Gamba MJ; Germán NF; Baños A; Gallino Yanzi J; Gálvez Elkin MS; Morbiducci JS; Martire MV; Maldonado Ficco H; Schmid MM; Villafañe Torres JA; de Los Ángeles Correa M; Medina MA; Cusa MA; Scafati J; Agüero SE; Lloves Schenone NM; Soriano ER; Graf C; Pons-Estel BA; Gomez G; Landi M; De la Vega MC; Pons-Estel GJ;
    Clin Rheumatol; 2023 Feb; 42(2):563-578. PubMed ID: 36201124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents.
    Fernandez-Gutierrez B; Leon L; Madrid A; Rodriguez-Rodriguez L; Freites D; Font J; Mucientes A; Culebras E; Colome JI; Jover JA; Abasolo L
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X20962692. PubMed ID: 33613703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.
    Sanchez-Piedra C; Diaz-Torne C; Manero J; Pego-Reigosa JM; Rúa-Figueroa Í; Gonzalez-Gay MA; Gomez-Reino J; Alvaro-Gracia JM;
    Ann Rheum Dis; 2020 Jul; 79(7):988-990. PubMed ID: 32503857
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases.
    Clemente D; Udaondo C; de Inocencio J; Nieto JC; Del Río PG; Fernández AG; Palomo JA; Bachiller-Corral J; Lopez Robledillo JC; Millán Longo C; Leon L; Abasolo L; Boteanu A
    Pediatr Rheumatol Online J; 2021 Nov; 19(1):162. PubMed ID: 34838054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous treatment adherence of patients with chronic inflammatory rheumatic diseases during the COVID-19 pandemic: experience of a single center.
    Konak HE; Armağan B; Güven SC; Atalar E; Karakaş Ö; Esmer S; Eksin MA; Polat B; Apaydin H; Gök K; Doğan İ; Erden A; Maraş Y; Küçükşahin O; Omma A; Erten Ş
    Rom J Intern Med; 2022 Sep; 60(3):173-181. PubMed ID: 35766218
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical course and outcomes of COVID-19 in rheumatic disease patients: a case cohort study with a diverse population.
    Arleo T; Tong D; Shabto J; O'Keefe G; Khosroshahi A
    Clin Rheumatol; 2021 Jul; 40(7):2633-2642. PubMed ID: 33420870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.
    Braun-Moscovici Y; Kaplan M; Braun M; Markovits D; Giryes S; Toledano K; Tavor Y; Dolnikov K; Balbir-Gurman A
    Ann Rheum Dis; 2021 Oct; 80(10):1317-1321. PubMed ID: 34144967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
    Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
    Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.